Literature DB >> 21088358

L-asparaginase-induced complete response in a relapsed patient with Epstein-Barr virus and cytotoxic peripheral T-cell lymphoma not otherwise specified.

Tsutomu Takahashi1, Fumiyoshi Ikejiri, Chie Onishi, Koshi Kawakami, Masaya Inoue, Takaaki Miyake, Junko Tanaka, Asuka Araki, Riruke Maruyama, Koichi Ohshima, Junji Suzumiya.   

Abstract

We present a patient with Epstein-Barr virus (EBV)-positive cytotoxic peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) who was successfully treated using only L-asparaginase. A 46-year-old Japanese man was diagnosed with EBV-positive cytotoxic PTCL-NOS. Although he underwent chemotherapy using multiple agents, he relapsed with hemophagocytic syndrome. L-asparaginase treatment was initiated at 6,000 U/m(2) on days 1, 3, 5, 10, and 12 together with prednisolone at 1 mg/kg. Although he developed grade 2 liver dysfunction and grade 2 coagulopathy, the patient achieved complete response status. Finally, he underwent allogeneic bone marrow stem cell transplantation, and he is currently still alive without disease at 24 months after the start of L-asparaginase therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088358     DOI: 10.2169/internalmedicine.49.4083

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma.

Authors:  Guoli Yao; De Zhou; Meng Zhou; Changqian Bao; Donghua He; Li Li; Jingjing Zhu; Jinsong He; Jimin Shi; Weiyan Zheng; Zhen Cai; He Huang; Xiujin Ye; Wanzhuo Xie
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Therapeutic options in peripheral T cell lymphoma.

Authors:  Yaping Zhang; Wei Xu; Hong Liu; Jianyong Li
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

3.  Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study.

Authors:  Yu Liu; Pingping Li; Liren Qian
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.